Traverse 2024 Testosterone. But that is only half the story. Older men with hypogonadism and high risk for cardiovascular disease who received.
— the traverse trial, a randomized controlled trial designed specifically to assess the cardiovascular safety of testosterone gel, has shown no increased cardiovascular risk and confirmed the drug’s relative safety. — a substudy of the randomized traverse trial showed no slowing of diabetes progression with testosterone therapy in hypogonadism.